Prostate Specific Antigen Antibody [A67-B/E3]

Cancer, Cell Cycle, Neuroscience, Signal Transduction

Flow Cytometry: 0.5-1 ug/million cells

IF: 0.5-1 ug/ml

IHC (FFPE): 0.5-1.0 ug/ml for 30 minutes at RT (1)

Prediluted format : incubate for 30 min at RT (2)

The concentration stated for each application is a general starting point. Variations in protocols, secondaries and substrates may require the PSA antibody to be titered up or down for optimal performance.

1. Staining of formalin-fixed tissues requires boiling tissue sections in 1mM EDTA Buffer, pH 7.5-8.5, for 10-20 min followed by cooling at RT for 20 minutes.
2. The prediluted format is supplied in a dropper bottle and is optimized for use in IHC. After epitope retrieval step (if required), drip mAb solution onto the tissue section and incubate at RT for 30 min.

Monoclonal

IgG1, kappa

PBS with 0.1 mg/ml BSA and 0.05% sodium azide

Aliquot and Store at 2-8˚ C. Avoid freez-thaw cycles.

None

354

KLK3

Homo sapiens

This antibody recognizes a single protein of 33-34kDa, identified as the Prostate specific antigen. This PSA antibody is highly specific and stains prostatic secretory and ductal epithelium in both normal and neoplastic tissues. Prostate specific antigen is a chymotrypsin-like serine protease (kallikrein family) exclusively produced by the prostate epithelium, and abundant in seminal fluid. PSA can be detected in the sera of patients with prostatic carcinoma. It is predominantly complexed to a liver-derived serine protease inhibitor, alpha-1-antichymotrypsin (ACT). A higher proportion of serum PSA is complexed to ACT in prostate cancer than in benign hyperplasia.

SDS-PAGE Analysis of Purified, BSA-Free PSA Antibody (A67-B/E3). Confirmation of Integrity and Purity of the Antibody.